Study Title
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Study Details
Description:
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Sponsor:
Peter MacCallum Cancer Centre
Contacts:
Shahneen Sandhushahneen.sandhu@petermac.org
+61 3 8559 7902
Michael Hofmanmichael.hofman@petermac.org
+61 3 8559 6914
Government Study Link:
NCT03874884 - Click here to see study onClinicalTrials.gov